Acorda Therapeutics Stock Price, News & Analysis (NASDAQ:ACOR)

$26.40 +0.30 (+1.15 %)
(As of 02/23/2018 09:42 AM ET)
Previous Close$26.10
Today's Range$26.00 - $26.75
52-Week Range$13.60 - $33.00
Volume518,600 shs
Average Volume778,217 shs
Market Capitalization$1.22 billion
P/E Ratio-5.45
Dividend YieldN/A
Beta1.63

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Debt-to-Equity Ratio0.64%
Current Ratio3.07%
Quick Ratio2.81%

Price-To-Earnings

Trailing P/E Ratio-5.45454545454545
Forward P/E Ratio-42.58
P/E GrowthN/A

Sales & Book Value

Annual Sales$588.29 million
Price / Sales2.10
Cash FlowN/A
Price / CashN/A
Book Value$11.12 per share
Price / Book2.37

Profitability

Trailing EPS($4.84)
Net Income$-223,350,000.00
Net Margins-37.97%
Return on Equity-4.88%
Return on Assets-2.41%

Miscellaneous

Employees597
Outstanding Shares46,750,000

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics Inc (NASDAQ:ACOR) announced its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported $0.61 EPS for the quarter, missing analysts' consensus estimates of $0.88 by $0.27. The biopharmaceutical company earned $188.40 million during the quarter, compared to analysts' expectations of $171.70 million. Acorda Therapeutics had a negative return on equity of 4.88% and a negative net margin of 37.97%. The business's revenue was up 34.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 EPS. View Acorda Therapeutics' Earnings History.

When will Acorda Therapeutics make its next earnings announcement?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Acorda Therapeutics.

Where is Acorda Therapeutics' stock going? Where will Acorda Therapeutics' stock price be in 2018?

13 Wall Street analysts have issued 12-month target prices for Acorda Therapeutics' shares. Their forecasts range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' stock price to reach $21.83 in the next year. View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:

  • 1. According to Zacks Investment Research, "Acorda ’s key multiple sclerosis drug Ampyra is facing patent challenges in the United States. Hence, Acorda’s dependence on Ampyra for a major part of its revenue is concerning. Presently, Acorda is also working on strengthening its Parkinson’s pipeline by focusing on its late stage candidates Inbrija (formerly known as CVT-301) in its portfolio. However, Inbrija recently received a refusal to file letter from the FDA which is concerning as it would delay its commercial launch. Moreover, the company has its share of pipeline setbacks too with the recent discontinuation of a late stage PD candidate tozadenant. On the flip side, Ampyra showed sequential improvements. Also, the company is also working on expanding its pipeline by entering into deals and pursuing acquisitions. The company’s share price has outperformed the industry in the last one year." (1/10/2018)
  • 2. HC Wainwright analysts commented, "Ziopharm’s CAR-T Programs Make a Splash at ASH; Reiterate Buy Ziopharm’s 2nd-gen CAR-T shows promise in early study. We attended the 2017 Annual Meeting of the American Society of Hematology (ASH) over the last weekend, where Ziopharm presented interim results from the ongoing Phase 1 clinical study in patients with CD19 + leukemia or lymphoma treated with Ziopharm’s second generation CD19 + CAR-T therapy. Recall, Ziopharm’s second generation CAR-T cells were manufactured using the company’s proprietary Sleeping Beauty (SB) transposon platform which shortens the manufacturing process to two weeks compared to the typical 3-4 weeks for currently approved CAR-T therapies, such as Kymriah from Novartis (NVS; not rated) and Yescarta from Gilead (GILD; not rated). The results from the Phase 1 study show that treatment of patients with relapsed/refractory leukemia or lymphoma (n = 8) resulted in a 50% complete response rate after one month of therapy." (12/14/2017)
  • 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)
  • 4. Stifel Nicolaus analysts commented, "Alexion (ALXN) reported 2Q17 sales/earnings and provided a business update (PDF) to investors. The company had a strong 2Q17, reporting sales of $912M and non-GAAP EPS of $1.56, beating OPCO by 9% and 25% respectively. The strong beat was partially attributable to favorable one-offs in 1H17, with 2H17 expected to see weaker growth, which was well flagged by the company. The pipeline keeps moving along with a positive opinion for Soliris rMG in the EU in June and a PDUFA date of Oct. 23, 2017. We were particularly struck by new management’s ability to stabilize the business, provide transparency and the continuing strong fundamentals." (7/28/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:

  • Ron Cohen, President,Chief Executive Officer, Director (Age 62)
  • Richard P. Batycky Ph.D., Chief Technology Officer and Site Head (Age 49)
  • David Lawrence, Chief Business Operations, Principal Accounting Officer (Age 59)
  • Andrew R. Blight Ph.D., Chief Scientific Officer (Age 66)
  • Jane Wasman J.D., President - International, General Counsel, Corporate Secretary (Age 61)
  • Burkhard Blank M.D., Chief Medical Officer (Age 62)
  • Andrew Hindman, Chief Business Development Officer (Age 44)
  • Lauren M. Sabella, Chief Commercial Officer (Age 56)
  • Barry E. Greene, Independent Director (Age 53)
  • Peder K. Jensen M.D., Independent Director (Age 62)

Who owns Acorda Therapeutics stock?

Acorda Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.88%), Spark Investment Management LLC (0.88%), Schwab Charles Investment Management Inc. (0.65%), Bogle Investment Management L P DE (0.53%), Two Sigma Advisers LP (0.48%) and Millennium Management LLC (0.43%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Who sold Acorda Therapeutics stock? Who is selling Acorda Therapeutics stock?

Acorda Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Gotham Asset Management LLC, TIAA CREF Investment Management LLC, Spark Investment Management LLC, Two Sigma Advisers LP, Alambic Investment Management L.P., Guggenheim Capital LLC, Geode Capital Management LLC and Metropolitan Life Insurance Co. NY. Company insiders that have sold Acorda Therapeutics company stock in the last year include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence and Lorin Randall. View Insider Buying and Selling for Acorda Therapeutics.

Who bought Acorda Therapeutics stock? Who is buying Acorda Therapeutics stock?

Acorda Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Millennium Management LLC, Arizona State Retirement System, Sphera Funds Management LTD., Virtus Fund Advisers LLC, Alliancebernstein L.P., Acadian Asset Management LLC and MetLife Investment Advisors LLC. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy Acorda Therapeutics stock?

Shares of Acorda Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of Acorda Therapeutics stock can currently be purchased for approximately $26.40.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $1.22 billion and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or ($4.84) on an earnings per share basis. Acorda Therapeutics employs 597 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (ACOR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  338 (Vote Underperform)
Total Votes:  595
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acorda Therapeutics (NASDAQ:ACOR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.152.002.002.33
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.83$20.33$20.67$24.67
Price Target Upside: 13.01% downside18.83% downside16.10% upside13.67% upside

Acorda Therapeutics (NASDAQ:ACOR) Consensus Price Target History

Price Target History for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ:ACOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018OppenheimerSet Price TargetHold$21.00LowView Rating Details
2/15/2018Piper Jaffray CompaniesUpgradeNeutral -> Overweight$25.10 -> $37.00HighView Rating Details
2/7/2018Goldman Sachs GroupUpgradeSell -> NeutralLowView Rating Details
1/17/2018HC WainwrightReiterated RatingBuy -> Buy$34.00 -> $31.00MediumView Rating Details
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLowView Rating Details
11/17/2017CowenReiterated RatingBuy$30.00N/AView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetHold$26.00 -> $17.00N/AView Rating Details
11/16/2017Raymond James FinancialDowngradeMarket Perform -> Underperform$7.00 -> $13.00N/AView Rating Details
11/16/2017Stifel NicolausDowngradeBuy -> Hold$26.00 -> $15.00N/AView Rating Details
11/15/2017Leerink SwannLower Price TargetMarket Perform$18.00N/AView Rating Details
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$18.00 -> $16.00N/AView Rating Details
11/9/2017CIBCInitiated CoverageMarket Perform -> Market PerformN/AView Rating Details
11/1/2017Jefferies GroupBoost Price TargetHold$22.00 -> $25.00N/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 -> $52.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Acorda Therapeutics (NASDAQ:ACOR) Earnings History and Estimates Chart

Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.68N/AView Earnings Details
2/15/2018Q4 2017$0.88$0.61$171.70 million$188.40 millionViewN/AView Earnings Details
10/31/2017Q3 2017$0.69$0.43$150.64 million$141.07 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.13$0.29$139.81 million$139.40 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
11/1/2010Q3 2010($0.12)$0.31ViewN/AView Earnings Details
8/3/2010Q2 2010($0.46)($0.18)ViewN/AView Earnings Details
4/30/2010Q1 2010($0.54)($0.56)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.60)($0.59)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.59)($0.52)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.54)($0.62)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.55)($0.50)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.52)($0.54)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.47)($0.53)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.47)($0.58)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.41)($0.45)ViewN/AView Earnings Details
2/11/2008Q4 2007($0.31)($0.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Acorda Therapeutics (NASDAQ:ACOR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.09$0.69$0.36
Q2 20183$0.49$0.84$0.68
Q3 20183($1.28)($0.10)($0.53)
Q4 20183($1.41)($0.65)($1.14)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Acorda Therapeutics (NASDAQ:ACOR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Acorda Therapeutics (NASDAQ ACOR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for Acorda Therapeutics (NASDAQ:ACOR)
Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2018David LawrenceInsiderSell31,000$27.58$854,980.005,275View SEC Filing  
12/1/2017Burkhard BlankInsiderSell11,050$20.53$226,856.5033,150View SEC Filing  
10/9/2017David LawrenceInsiderSell250$25.40$6,350.00View SEC Filing  
8/29/2017Scopia Capital Management LpMajor ShareholderBuy766,201$19.23$14,734,045.23View SEC Filing  
8/1/2017Barry E GreeneDirectorSell10,000$21.57$215,700.0010,000View SEC Filing  
7/31/2017Lorin RandallDirectorSell10,000$21.66$216,600.0010,000View SEC Filing  
6/16/2017Ron CohenInsiderBuy20,000$16.95$339,000.00511,648View SEC Filing  
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.0046,123View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00519,860View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.9045,916View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.008,952View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00105,021View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00109,271View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.009,702View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.381,086View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.6049,670View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.841,488View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10100,124View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.5214,378View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00108,579View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.389,202View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.0014,378View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.4432,148View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00400,550View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.0071,659View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.0041,677View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.5098,097View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00412,400View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.5071,659View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.5712,403View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.4032,527View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00105,459View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00478,868View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acorda Therapeutics (NASDAQ ACOR) News Headlines

Source:
DateHeadline
Form 4 ACORDA THERAPEUTICS INC For: Feb 17 Filed by: STRADER CATHERINE D.Form 4 ACORDA THERAPEUTICS INC For: Feb 17 Filed by: STRADER CATHERINE D.
www.streetinsider.com - February 22 at 8:55 AM
FDA Accepts Acorda's NDA for Parkinson's Disease CandidateFDA Accepts Acorda's NDA for Parkinson's Disease Candidate
finance.yahoo.com - February 21 at 4:59 PM
FDA Accepts Acordas NDA for Parkinsons Disease CandidateFDA Accepts Acorda's NDA for Parkinson's Disease Candidate
www.zacks.com - February 21 at 9:01 AM
BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For InbrijaBRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija
www.reuters.com - February 20 at 8:48 AM
Acorda Therapeutics (ACOR) Raised to Neutral at Goldman Sachs GroupAcorda Therapeutics (ACOR) Raised to Neutral at Goldman Sachs Group
www.americanbankingnews.com - February 20 at 12:24 AM
Acorda Therapeutics (ACOR) Stock Rating Upgraded by ValuEngineAcorda Therapeutics (ACOR) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 17 at 1:54 PM
Oppenheimer Analysts Give Acorda Therapeutics (ACOR) a $21.00 Price TargetOppenheimer Analysts Give Acorda Therapeutics (ACOR) a $21.00 Price Target
www.americanbankingnews.com - February 16 at 6:34 PM
Acorda Therapeutics, Inc. 2017 Q4 - Results - Earnings Call SlidesAcorda Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - February 16 at 4:53 PM
Acorda Therapeutics (ACOR) Lifted to "Buy" at Piper Jaffray CompaniesAcorda Therapeutics (ACOR) Lifted to "Buy" at Piper Jaffray Companies
www.americanbankingnews.com - February 15 at 6:20 PM
Acorda reports 4Q lossAcorda reports 4Q loss
finance.yahoo.com - February 15 at 4:53 PM
Acorda Therapeutics Inc (NASDAQ:ACOR): Does -148.17% Earnings Drop In A Year Reflect The Long-Term Trend?Acorda Therapeutics Inc (NASDAQ:ACOR): Does -148.17% Earnings Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - February 15 at 4:53 PM
Acorda Therapeutics (ACOR) Posts  Earnings Results, Misses Expectations By $0.39 EPSAcorda Therapeutics (ACOR) Posts Earnings Results, Misses Expectations By $0.39 EPS
www.americanbankingnews.com - February 15 at 3:14 PM
Acorda Therapeutics, Inc. to Host Earnings CallAcorda Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - February 15 at 8:27 AM
Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017
finance.yahoo.com - February 15 at 8:27 AM
Acorda Therapeutics Inc (ACOR) Receives Consensus Recommendation of "Hold" from AnalystsAcorda Therapeutics Inc (ACOR) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 14 at 3:26 PM
 Analysts Anticipate Acorda Therapeutics Inc (ACOR) Will Announce Quarterly Sales of $174.49 Million Analysts Anticipate Acorda Therapeutics Inc (ACOR) Will Announce Quarterly Sales of $174.49 Million
www.americanbankingnews.com - February 11 at 2:44 AM
Acorda Therapeutics (ACOR) Rating Lowered to Sell at ValuEngineAcorda Therapeutics (ACOR) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - February 9 at 11:46 PM
Zacks: Analysts Expect Acorda Therapeutics Inc (ACOR) Will Announce Earnings of $1.09 Per ShareZacks: Analysts Expect Acorda Therapeutics Inc (ACOR) Will Announce Earnings of $1.09 Per Share
www.americanbankingnews.com - February 9 at 5:14 PM
Critical Survey: Intra-Cellular Therapies (ITCI) versus Acorda Therapeutics (ACOR)Critical Survey: Intra-Cellular Therapies (ITCI) versus Acorda Therapeutics (ACOR)
www.americanbankingnews.com - February 9 at 5:10 AM
Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceAcorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 8 at 8:39 AM
Options Traders Expect Huge Moves in Acorda Therapeutics (ACOR) StockOptions Traders Expect Huge Moves in Acorda Therapeutics (ACOR) Stock
finance.yahoo.com - February 6 at 4:10 PM
Acorda Therapeutics (ACOR) Scheduled to Post Earnings on MondayAcorda Therapeutics (ACOR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 3:12 AM
Acorda Fourth Quarter/Year End 2017 Update - Business Wire (press release)Acorda Fourth Quarter/Year End 2017 Update - Business Wire (press release)
www.businesswire.com - February 2 at 4:16 PM
Acorda Therapeutics Inc (ACOR) to Post FY2017 Earnings of ($0.05) Per Share, Oppenheimer ForecastsAcorda Therapeutics Inc (ACOR) to Post FY2017 Earnings of ($0.05) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - February 2 at 7:42 AM
Analysts Set Expectations for Acorda Therapeutics Incs Q2 2018 Earnings (ACOR)Analysts Set Expectations for Acorda Therapeutics Inc's Q2 2018 Earnings (ACOR)
www.americanbankingnews.com - February 1 at 10:24 AM
Acorda Therapeutics (ACOR) PT Raised to $21.00Acorda Therapeutics (ACOR) PT Raised to $21.00
www.americanbankingnews.com - January 31 at 3:22 PM
 Analysts Anticipate Acorda Therapeutics Inc (ACOR) Will Announce Quarterly Sales of $169.48 Million Analysts Anticipate Acorda Therapeutics Inc (ACOR) Will Announce Quarterly Sales of $169.48 Million
www.americanbankingnews.com - January 25 at 1:58 AM
Active-Investors: Blog Exposure - Acorda Therapeutics Stock Surges Amidst Rumors Of TakeoverActive-Investors: Blog Exposure - Acorda Therapeutics' Stock Surges Amidst Rumors Of Takeover
www.finanznachrichten.de - January 23 at 10:52 AM
Form 4 ACORDA THERAPEUTICS INC For: Jan 18 Filed by: LAWRENCE DAVID - StreetInsider.comForm 4 ACORDA THERAPEUTICS INC For: Jan 18 Filed by: LAWRENCE DAVID - StreetInsider.com
www.streetinsider.com - January 22 at 3:27 PM
Blog Exposure - Acorda Therapeutics’ Stock Surges Amidst Rumors Of TakeoverBlog Exposure - Acorda Therapeutics’ Stock Surges Amidst Rumors Of Takeover
finance.yahoo.com - January 22 at 3:27 PM
Today’s Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst PharmaceuticalsToday’s Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst Pharmaceuticals
finance.yahoo.com - January 22 at 3:27 PM
Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%
finance.yahoo.com - January 22 at 3:27 PM
Insider Selling: Acorda Therapeutics Inc (ACOR) Insider Sells 31,000 Shares of StockInsider Selling: Acorda Therapeutics Inc (ACOR) Insider Sells 31,000 Shares of Stock
www.americanbankingnews.com - January 22 at 9:32 AM
Acorda Therapeutics Inc (ACOR) Given Average Rating of "Hold" by AnalystsAcorda Therapeutics Inc (ACOR) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 20 at 5:38 PM
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors - MarketWatchAcorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors - MarketWatch
www.marketwatch.com - January 20 at 7:24 AM
Form 8-K/A ACORDA THERAPEUTICS INC For: Jan 19 - StreetInsider.comForm 8-K/A ACORDA THERAPEUTICS INC For: Jan 19 - StreetInsider.com
www.streetinsider.com - January 20 at 7:24 AM
Heres Why Acorda Therapeutics Inc. Stock Is Surging TodayHere's Why Acorda Therapeutics Inc. Stock Is Surging Today
www.fool.com - January 19 at 1:53 PM
Acorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitorsAcorda shares jump 20% premarket on talk of possible takeover by Biogen, other suitors
www.marketwatch.com - January 19 at 9:13 AM
Form 8-K/A ACORDA THERAPEUTICS INC For: Jan 19Form 8-K/A ACORDA THERAPEUTICS INC For: Jan 19
www.streetinsider.com - January 19 at 9:13 AM
Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACORKessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR
finance.yahoo.com - January 17 at 11:36 AM
FINAL SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018FINAL SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) and Lead Plaintiff Deadline: January 17, 2018
finance.yahoo.com - January 17 at 11:36 AM
Kessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACORKessler Topaz Meltzer & Check, LLP - SHAREHOLDER REMINDER:  Deadline in Class Action Lawsuit Filed Against Acorda Therapeutics, Inc. – ACOR
finance.yahoo.com - January 17 at 11:36 AM
FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Acorda Therapeutics, Inc. (ACOR) & Lead Plaintiff Deadline - January 17, 2018
finance.yahoo.com - January 16 at 3:22 PM
DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACORDEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - January 16 at 3:22 PM
IMPORTANT STOCKHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline NearsIMPORTANT STOCKHOLDER NOTICE: Brodsky & Smith, LLC Reminds Acorda Therapeutics, Inc. (ACOR) Stockholders That Important Deadline Nears
finance.yahoo.com - January 15 at 3:22 PM
ACOR UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018ACOR UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Acorda Therapeutics, Inc. and a Lead Plaintiff Deadline of January 17, 2018
finance.yahoo.com - January 15 at 3:22 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACORSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Acorda Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 17, 2018 - ACOR
finance.yahoo.com - January 14 at 3:22 PM
Stock Traders Buy Large Volume of Acorda Therapeutics Call Options (ACOR)Stock Traders Buy Large Volume of Acorda Therapeutics Call Options (ACOR)
www.americanbankingnews.com - January 14 at 3:40 AM
ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in ... - GlobeNewswire (press release)ACOR ALERT: Rosen Law Firm Reminds Acorda Therapeutics, Inc. Investors of Important January 17 Deadline in ... - GlobeNewswire (press release)
globenewswire.com - January 13 at 7:53 AM
Traders Buy High Volume of Put Options on Acorda Therapeutics (ACOR)Traders Buy High Volume of Put Options on Acorda Therapeutics (ACOR)
www.americanbankingnews.com - January 13 at 2:04 AM

SEC Filings

Acorda Therapeutics (NASDAQ:ACOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acorda Therapeutics (NASDAQ:ACOR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acorda Therapeutics (NASDAQ ACOR) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.